Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

Negative list

Published:

|

Updated:

Changes

  • : Kaliumcitrat lagt til listen, gjeldende fra 01.02.2025.

Here you will find an overview of product groups and products that cannot be dispensed before the Norwegian Medical Products Agency (NOMA) has assessed the application for compassionate use, named patient.

  1. Medicines (including foreign pharmacy-compounded medicines) that do not have marketing authorisation in the EEA, USA, PIC/S countries, or countries with an MRA agreement
    Exceptions on the dispensing list.
  2. Medical Gases
    Applications for compassionate use, named patient must be assessed by NOMA before dispensing. Applications related to medical gases are sent directly to the gas supplier, who then forwards the application to NOMA.
  3. Other Medicines 

Active Substance 

Example Trade Name 

Comment 

Assessment Date 

Cannabis Products 

Bedrocan 

Only specialists employed at hospitals can apply for compassionate use, named patient for medical cannabis with more than 1% THC. 

09.06.2022 

Deflazacort Tablets 

Calcort 

There is a marketed product (Deflazacort Vital Pharma Nordic tablets 6 mg). NOMA must assess the use of non-marketed products. 

01.03.2023 

Dexamfetamine Tablet 

Metamina 

There is a marketed product (Attentin). NOMA must assess the use of non-marketed products. 

09.06.2022 

Dexchlorpheniramine 2 mg 

Polaramine 

There is a marketed product (Aniramin 2 mg). NOMA must assess the use of non-marketed products. 

15.09.2023 

Dronabinol 

Marinol 

Only specialists employed at hospitals can apply for compassionate use, named patient for medical cannabis with more than 1% THC. 

09.06.2022 

Heroin 

Diaphin 

Prohibited under §5 of the Narcotics Regulations and requires a requisition permit from the Norwegian Directorate of Health. 

09.06.2022 

Hydrocortisone Tablets 

Cortef, Hydrocortisone 

There is a marketed product (Lilinorm 5 and 10 mg). NOMA must assess the use of non-marketed products. 

01.01.2023 

Idebenone 

- 

There is a marketed product (Raxone) that should be used for the approved indication. NOMA can assess compassionate use, named patient for other indications. 

09.06.2022 

Iodinated Povidone Eye Drops 

Betadine 

There is a marketed product (Ophthajod eye drops, solution 50 mg/ml). NOMA must assess the use of non-marketed products. 

01.08.2023 

Potassium citrate tablets with modified release 1080 mg

Urocit-K, Acalka

Rhere is a marketed product (Alkacit tablets with modified release 1080 mg) that should be used for the approved indication. NOMA can assess compassionate use, named patient for other indications. 

01.02.2025

Mexiletine Hydrochloride 

Mexiletine, Mexitil 

There is a marketed product (Namuscla) that should be used for the approved indication. NOMA can assess compassionate use, named patient for other indications. 

04.08.2022 

Oxybutynin 5 mg Tablets 

Dridase 

There is a marketed product (Oxybutynin Macure 5 mg tablets) that should be used. 

01.04.2024 

Thiamine (Vitamin B1) Injection 

- 

There is a marketed product (Thiamine Sterop 50 mg/ml and 125 mg/ml). NOMA must assess the use of non-marketed products. 

01.03.2020